Chardan Capital, led by analyst Geulah Livshits, has reaffirmed its positive outlook on Immuneering (IMRX, Financial). As of May 6, 2025, the firm maintains its "Buy" rating on IMRX, indicating continued confidence in the stock's potential.
The price target for Immuneering (IMRX, Financial) remains steady at $13.00 USD, unchanged from the prior target. This consistent price target suggests that Chardan Capital anticipates stable performance from the company moving forward.
Investors in Immuneering (IMRX, Financial) can rely on this latest assessment from Chardan Capital as an indication of the firm's unchanged sentiment towards the stock's future prospects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Immuneering Corp (IMRX, Financial) is $12.10 with a high estimate of $25.00 and a low estimate of $1.50. The average target implies an upside of 868.00% from the current price of $1.25. More detailed estimate data can be found on the Immuneering Corp (IMRX) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Immuneering Corp's (IMRX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
